Cite
MLA Citation
Stephen L Hauser et al.. “Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.” Multiple sclerosis, vol. 28, 2022, pp. 1576–1590. http://access.bl.uk/ark:/81055/vdc_100156803845.0x000018